Jeff Bronstein, MD
Neurology · Los Angeles, CANPI 1114940731
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,025 of the $15,736 with a category attached, or 89.1%. AstraZeneca accounts for 75.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $5,188 and has fallen 69.3% since, to $1,595 in 2025.
Across 23 payments — averaging $684.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- Ultragenyx Pharmaceutical Inc.$2K
- Bayer$2K
- AbbVie$69
- Pfizer$23
- MDD US Operations, LLC$13
- plus $11 from 1 others
Across 94 payments — averaging $7838.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$318K
- AstraZeneca$275K
- AbbVie$103K
- MDD US Operations, LLC$41K
What the payments were for
- Consulting fees$14,02589%
- Travel & lodging$1,2278%
- Food & beverage$4843%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $11,825 |
| Ultragenyx Pharmaceutical Inc. | 1 | $2,200 |
| Bayer | 10 | $1,595 |
| AbbVie | 3 | $69 |
| Pfizer | 1 | $23 |
| MDD US Operations, LLC | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $11 |
How this compares
$15,736 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 174 | $1,155,136 |
| ApokynApomorphine Hcl | 11 | $832,654 |
| RytaryCarbidopa/Levodopa | 148 | $166,624 |
| GocovriAmantadine Hcl | 34 | $122,001 |
| NourianzIstradefylline | 31 | $71,852 |
| OngentysOpicapone | 54 | $46,144 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 118 | $32,057 |
| NeuproRotigotine | 13 | $21,900 |
| MyrbetriqMirabegron | 37 | $21,196 |
| Rasagiline Mesylate | 91 | $20,708 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 202 | $17,021 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 285 | $15,089 |
| Entacapone | 21 | $12,719 |
| MotegrityPrucalopride Succinate | 13 | $9,473 |
| Modafinil | 12 | $7,538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $11 | $1,155,136174 claims |
| MDD US Operations, LLCGocovri | $13 | $122,00134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.